Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 2/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | NAAA | Q02083 | 4/20 | 0.43 |
| ▸ | PLA2G6 | O60733 | 2/20 | 0.41 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.41 |
| ▸ | PSEN1 | P49768 | 4/20 | 0.40 |
| ▸ | PSEN2 | P49810 | 4/20 | 0.40 |
| ▸ | APH1B | Q8WW43 | 4/20 | 0.40 |
| ▸ | NCSTN | Q92542 | 4/20 | 0.40 |
| ▸ | APH1A | Q96BI3 | 4/20 | 0.40 |
| ▸ | PSENEN | Q9NZ42 | 4/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
| ▸ | TACR2 | P21452 | 2/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18080620 | 0.96 | NAAA (0.43) | BCHEACHENAAAPLA2G6PLA2G4A | |
| SCHEMBL16805385 | 0.96 | NAAA (0.43) | BCHEACHENAAAPLA2G6PLA2G4A | |
| SCHEMBL26533871 | 0.90 | PSEN1 (0.45) | BCHEACHENAAAPLA2G6PLA2G4A | |
| SCHEMBL12869515 | 0.89 | NAAA (0.41) | BCHEACHENAAAPLA2G6PLA2G4A | |
| SCHEMBL12869511 | 0.89 | NAAA (0.41) | BCHEACHENAAAPLA2G6PLA2G4A | |
| SCHEMBL769853 | 0.89 | NAAA (0.41) | BCHEACHENAAAPLA2G6PLA2G4A | |
| SCHEMBL10177147 | 0.89 | NAAA (0.41) | BCHEACHENAAAPLA2G6PLA2G4A | |
| SCHEMBL18522464 | 0.89 | NAAA (0.41) | BCHEACHENAAAPLA2G6PLA2G4A | |
| SCHEMBL22710203 | 0.86 | BCHE (0.45) | BCHEACHEPSEN1PSEN2APH1B | |
| SCHEMBL22330780 | 0.84 | BCHE (0.56) | BCHEACHEPDPK1MTORTACR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160108078-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-04-21 | — | — | US | disclosed |
| US-20140296506-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-10-02 | — | — | US | disclosed |
| US-8785403-B2 | Glucopyranoside compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-07-22 | — | — | US | disclosed |
| US-20120258913-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-10-11 | — | — | US | disclosed |
| US-8222219-B2 | Glucopyranoside compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-07-17 | — | — | US | disclosed |
| US-8202984-B2 | Glucopyranoside compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-06-19 | — | — | US | disclosed |
| US-20120058941-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20110275703-A1 | SUBSTITUTED SPIROKETAL DERIVATIVES AND USE THEREOF AS THERAPEUTIC DRUG FOR DIABETES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-11-10 | — | — | US | disclosed |
| US-20110105424-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058941-A1 | GLUCOPYRANOSIDE COMPOUND | UGGT1, B3GAT3, FUT6 | BCHE 2233/4885ACHE 2302/4885NAAA 1172/4885 |
| US-20110105424-A1 | GLUCOPYRANOSIDE COMPOUND | UGGT1, B3GAT3, FUT6 | BCHE 2233/4885ACHE 2302/4885NAAA 1172/4885 |
| US-20120258913-A1 | GLUCOPYRANOSIDE COMPOUND | UGGT1, B3GAT3, FUT6 | BCHE 2233/4885ACHE 2302/4885NAAA 1172/4885 |
| US-20110275703-A1 | SUBSTITUTED SPIROKETAL DERIVATIVES AND USE THEREOF AS THERAPEUTIC DRUG FOR DIABETES | SLC5A1, OR10J3, AKR1C3 | BCHE 3589/4885ACHE 3750/4885NAAA 4304/4885 |
| US-20160108078-A1 | GLUCOPYRANOSIDE COMPOUND | UGGT1, B3GAT3, FUT6 | BCHE 2233/4885ACHE 2302/4885NAAA 1172/4885 |
| US-20140296506-A1 | GLUCOPYRANOSIDE COMPOUND | UGGT1, B3GAT3, FUT6 | BCHE 2233/4885ACHE 2302/4885NAAA 1172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.